CDER New Drug Reviews Are At 80%-90% Of User Fee Goals, Jenkins Says

The Center for Drug Evaluation and Research's performance in review applications for new drugs and biologics within the timelines specified by the Prescription Drug User Fee Act has slipped to 80 percent to 90 percent